The issue of aftercare for participants in clinical research was explored in the context of an asthma drug trial.
Introduction
The concept that research subjects deserve to be compensated for research-related injuries was first promulgated in the 1960s, considered by a number of government agencies in the 1970s, and gained general acceptance in the 1 980s when it was included in the International Guidelines for Biomedical Research Involving Human Subjects, published by the World Health Organisation and Council for International Organisations of Medical Sciences (1,2).
While not yet incorporated into law, there is such a prospect sometime in the 1990s (3) . This concept is based on the ethical principle of distributive justice, where society as a whole, which stands to gain from advances in medical knowledge, owes a debt to those of its members who assume increased risks as research subjects to provide the benefits of research to society (1, 3) .
This concept may be taken one step further to imply some moral obligation on the part of society, sponsors and clinical investigators for the welfare of Key words Human experimentation; aftercare; compensation; research injuries. research subjects after the completion of clinical trials, and indeed, such an extension has been considered by the current European Good Clinical Practice (GCP) guidelines, which state that 'the investigator is medically responsible for those subjects who are under his/her care for the duration of the trial and must ensure that appropriate medical care is maintained after the trial' (4) . However, such an extension would be financially prohibitive in the case of subjects with chronic diseases, and the financial burden of providing hospital, medical care and medications for research subjects beyond the duration of the clinical trial would deter even the most affluent of pharmaceutical companies from doing clinical trials for chronic diseases. In this study, we explored the ethical justifications and practical ramifications of this concept in the context of a clinical drug trial for asthma, a chronic disease in children (5) (6) (7) (8) .
Asthma is a chronic respiratory illness characterised by airway inflammation, resulting in recurrent and reversible airway obstruction. The mainstay of treatment consists of regular administration of bronchodilators (for example, theophylline, betaagonists) and/or anti-inflammatory agents (for example, cromoglycate, corticosteroids). For about half the children diagnosed with asthma, significant symptoms persist into adult life (9, 10) . This issue of aftercare for children with asthma recruited into our clinical trial of ketotifen (5), a drug as yet unlicensed in Australia, was discussed with our commercial sponsor. The company agreed to provide the drug free-of-charge to all the children under a 'compassionate use' protocol until such time as it became licensed under the Pharmaceutical Benefits Scheme, where it would be either free or subsidised by government, depending on a means test. The question of medical and hospital aftercare for the children was not a major consideration because of universal health cover in Australia. A more relevant question was whether the parents of these children would gain enough information about asthma management during the course of the clinical trial, or whether there would be a need to provide a formal, structured asthma education programme, similar to those shown to be effective in reducing morbidity in this disease (11, 12) . As part of this consideration, we decided to assess the knowledge and attitudes of the parents at the end of the trial to determine the need for providing structured education programmes to these patients.
Methods
The subjects for the present study were recruited from parents who had volunteered their children for a randomised, double-blind, placebo-controlled trial of ketotifen, a new and unlicensed oral asthma drug (5) (6) (7) (8) For the present study we used a 77-item questionnaire, each with five to ten questions which was developed to assess the knowledge, attitudes, compliance and misconceptions about asthma and its treatment (13) (14) (15) (16) . The parent most involved in the child's asthma management was asked to complete the questionnaire. Detailed sociodemographic information was also obtained. The completed questionnaires were coded and analysed by computer using the SAS statistical package (17 (18, 19) . Our own study of parents who volunteered their children for clinical research confirmed that volunteering parents were socially disadvantaged, emotionally vulnerable and psychologically predisposed to volunteering (6, 7) . In reality, there is a little bit of altruistic hero, giftgiver, opportunist, willing contractor and victim in all research subjects, and it is indeed the current consensus (1,3) that it would be not only uncharitable but also unjust to deny compensation, and by extension good medical aftercare, to these individuals.
Continuing supplies
The issue of aftercare for participants in clinical research was examined in the context of an asthma drug trial in children in terms of its practical limitations. Because of universal health cover in Australia, the long term medical care of these children including their need for hospitalisation did not present itself as a relevant issue. More relevant was the responsibility ofproviding the children with continuing supplies of the medication used in the clinical trial for as long as it is needed, but it was considered too financially burdensome by our commercial sponsor, so a compromise was reached to provide it free-of-charge until it becomes licensed and government-subsidised under the Pharmaceutical Benefits Scheme. As it turned out, there was no need to invoke this provision because the drug (ketotifen) was shown to be ineffective in the children concerned (5) . A third issue was whether the parents would have gained enough knowledge from the clinical trial to manage their children's asthma better. The data showed that although their understanding of the aetiology of asthma was better than the comparison group, their overall level of knowledge was quite poor and no better than the comparison group. Attitudes are important predeterminants of behaviour, and in this regard, they were more negative about their children's asthma, more compliant with medications and more trusting of orthodox medicine than the comparison group. These findings indicate that the participating parents would benefit from enrolment in an asthma education programme. As it turned out, we were able to provide the children and parents in our study with continuing care and the benefits of an asthma education programme because of special funding from the Australian Department of Health, Housing and Human Services (20) .
While the practical issues of aftercare for our particular group of research subjects and their parents appear to be amenable to a problem-solving approach, our In conclusion, the issue of aftercare for research subjects is fraught with practical difficulties and ethical complexities. This study, the first of its kind to explore this neglected area of clinical ethics, may provide a stimulus for the wider discussion of the ethics of post-trial practices.
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